Stoke Therapeutics Inc. Common Stock (STOK)

FairStock Score: 28/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look for durable earning power bought at a sensible price. Stoke Therapeutics is a clinical-stage biotechnology company using its TANGO antisense approach to try to restore protein levels for severe genetic diseases. The science may be promising, but the business is not yet proven. In fiscal Q2 2026, the quarter ended 2026-06-30, revenue was $9.3M and net loss was $61.6M, or diluted EPS -$0.93. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $6.2M and net loss was $50.0M. Those are heavy losses against a $1.5B market cap at the 2026-10-13 close of $22.50. FairStock's P/E is -6.64, which simply says there are no positive earnings to value; its P/B is 4.06 and ROE is -61.10%, showing investors pay a premium for assets while returns are deeply negative. The income statement is volatile: in fiscal 2025, the year ended 2025-12-31, revenue was $184.4M and net loss was $6.9M; in fiscal 2024, the year ended 2024-12-31, revenue was $36.6M and net loss was $89.0M. Trailing free cash flow was -$180.7M, a -12.4% FCF yield per FairStock. Debt is low at D/E 0.01, but cash burn is the real issue. Piotroski 3/9 and FairStock score 28/100 suggest weak fundamental momentum. The moat, if any, rests on patents, trial data, and regulatory success, none of which are assured. The Lynch category is none because it lost money in each of the last four years. I would treat this as a speculative pipeline bet, not a Graham bargain.

In plain English: Stoke Therapeutics is a biotechnology company working on medicines for severe genetic diseases by trying to restore missing proteins. The business is not profitable, it is burning cash, and its recent losses are large compared with its revenue. At the $22.50 close on 2026-10-13, the $1.5B market value looks expensive relative to today's numbers and depends on future pipeline success.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer